ArticleGastrointestinal cancer research : GCR2008
Esophageal cancer chemotherapy: recent advances.
Article in Gastrointestinal cancer research : GCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2012Pooled it
- Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.Cancer communications (London, England) · 2019Trial
- Evaluation and comparison of the anti-proliferative and anti-metastatic effects of urolithin A and urolithin B against esophageal cancer cells: an in vitro and in silico study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- The neoadjuvant esophageal score: a prognostic tool for predicting survival and postoperative complications in esophageal squamous cell carcinoma.Frontiers in immunology · 2025Article
- Utilising systematic reviews to assess potential overtreatment and claim for better evidence-based research: an analysis of anticancer drugs versus supportive care in advanced esophageal cancer.Systematic reviews · 2024Article
- The Role of Long Noncoding RNAs (lncRNAs) in Esophageal Cancer Therapy Resistance and Metastasis.Biomedicines · 2024Review
- Gastrointestinal tumor-related perihepatic fluorouracil encapsulated lesions and liver metastases: a diagnostic imaging study based on contrast-enhanced computed tomography and magnetic resonance imaging.Quantitative imaging in medicine and surgery · 2023Article
- Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer.JTO clinical and research reports · 2022Article
- FAT1 downregulation enhances stemness and cisplatin resistance in esophageal squamous cell carcinoma.Molecular and cellular biochemistry · 2022Article
- Cardiopulmonary Exercise Testing as a Predictor of Postoperative Outcome in Patients Undergoing Oesophageal Cancer Surgery Following Neoadjuvant Chemotherapy.Turkish journal of anaesthesiology and reanimation · 2022Article
- Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4.British journal of cancer · 2022Article
- Baicalein and Αlpha-Tocopherol Inhibit Toll-like Receptor Pathways in Cisplatin-Induced Nephrotoxicity.Molecules (Basel, Switzerland) · 2022Article
- Molecular mechanisms associated with chemoresistance in esophageal cancer.Cellular and molecular life sciences : CMLS · 2022Review
- Intravenous Administration of Cisplatin with Magnesium Sulfate Supplement May Prevent Kidney Toxicity in Rats: The Role of Gender and Magnesium Sulfate Dose.International journal of nephrology · 2022Article
- Ursolic Acid Accelerates Paclitaxel-Induced Cell Death in Esophageal Cancer Cells by Suppressing Akt/FOXM1 Signaling Cascade.International journal of molecular sciences · 2021Article
- Article
- Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma.Molecular oncology · 2021Article
- How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy.International journal of molecular sciences · 2021Review
- Blockade of TRIM59 enhances esophageal cancer cell chemosensitivity to cisplatin by upregulating p53.Oncology letters · 2021Article
- Influence of Polymer Composition on the Controlled Release of Docetaxel: A Comparison of Non-Degradable Polymer Films for Oesophageal Drug-Eluting Stents.Pharmaceutics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer, though relatively uncommon in the United States, is a major global health threat. Squamous cell carcinoma remains the most common histology worldwide, whereas adenocarcinoma of the esophagus is increasing at epidemic proportions in the United States and other Western countries. Both histologies carry a poor prognosis: 5-year mortality for esophageal cancer exceeds 85% to 90%. Locally advanced esophageal cancer treated with the standard approaches of surgery or radiotherapy is associated with poor prognosis, due to both a high incidence of local-regional treatment failure and early systemic dissemination of disease. The obvious need to address the early spread of esophageal carcinoma through systemic treatment has led to the study of combined-modality therapies incorporating chemotherapy. Concurrent chemotherapy and radiotherapy is now a standard of care in the nonsurgical management of locally advanced esophageal cancer. Preoperative chemotherapy and combined preoperative chemoradiotherapy are also standards of treatment based on recent clinical trials. With the increasing use of chemotherapy as part of operative management as well, systemic chemotherapy will ultimately be used to treat the majority of patients with esophageal cancer. This article reviews results of recent clinical trials in the use of single-agent chemotherapy, combination chemotherapy, targeted agents, and neoadjuvant chemotherapy in the treatment of esophageal cancer.
Identifiers
19259300PMC2630822W97409349What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.